TY - JOUR
T1 - Safety and efficacy of plasma exchange in pediatric transverse myelitis
AU - Noland, Daniel K.
AU - Greenberg, Benjamin M.
N1 - Funding Information:
D.K. Noland estimates 50% effort spent performing clinical apheresis. B.M. Greenberg has received funding for travel from Transverse Myelitis Association; has filed patents on the use of antibody suppression in multiple sclerosis; serves as a consultant for Novartis, Alexion, and EMD Serono; and receives research support from Genentech, Medimmune, Chugai, Medday, NIH, University of Texas Southwestern, Transverse Myelitis Association, the Guthy Jackson Charitable Foundation, the National MS Society, and PCORI. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
Publisher Copyright:
© 2018 American Academy of Neurology.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Background We sought to review safety and efficacy of therapeutic plasma exchange (TPE) in a cohort of pediatric patients with transverse myelitis. Methods Billing data of all plasma exchanges performed at our tertiary care pediatric hospital between August 2010 and August 2016 were compared to electronic medical records to find all patients whose indication for apheresis was transverse myelitis. Patient outcomes were quantified on the modified Rankin Scale. Results Fifteen of 19 patients (79%) had major improvement in symptoms after a course of 4-7 therapeutic plasma exchanges. The majority required further inpatient (6, 32%) or outpatient (8, 42%) physical therapy. Four (21%) patients returned to baseline and over 75% regained their ability to ambulate as of last follow-up. Four adverse events were noted over 114 treatments. Conclusions TPE can be a useful treatment for pediatric transverse myelitis. The retrospective nature of this study without a comparator group limits conclusions about efficacy. However, controlled trials would help to validate our results. Classification of evidence This study provides Class IV evidence that plasma exchange is safe and effective in pediatric transverse myelitis.
AB - Background We sought to review safety and efficacy of therapeutic plasma exchange (TPE) in a cohort of pediatric patients with transverse myelitis. Methods Billing data of all plasma exchanges performed at our tertiary care pediatric hospital between August 2010 and August 2016 were compared to electronic medical records to find all patients whose indication for apheresis was transverse myelitis. Patient outcomes were quantified on the modified Rankin Scale. Results Fifteen of 19 patients (79%) had major improvement in symptoms after a course of 4-7 therapeutic plasma exchanges. The majority required further inpatient (6, 32%) or outpatient (8, 42%) physical therapy. Four (21%) patients returned to baseline and over 75% regained their ability to ambulate as of last follow-up. Four adverse events were noted over 114 treatments. Conclusions TPE can be a useful treatment for pediatric transverse myelitis. The retrospective nature of this study without a comparator group limits conclusions about efficacy. However, controlled trials would help to validate our results. Classification of evidence This study provides Class IV evidence that plasma exchange is safe and effective in pediatric transverse myelitis.
UR - http://www.scopus.com/inward/record.url?scp=85060822117&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060822117&partnerID=8YFLogxK
U2 - 10.1212/CPJ.0000000000000480
DO - 10.1212/CPJ.0000000000000480
M3 - Article
C2 - 30140584
AN - SCOPUS:85060822117
SN - 2163-0402
VL - 8
SP - 327
EP - 330
JO - Neurology: Clinical Practice
JF - Neurology: Clinical Practice
IS - 4
ER -